- Home
- GLRE vs ZURA Comparison
GLRE vs ZURA Comparison
Compare GLRE & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLRE | ZURA |
|---|---|---|
| Founded | 2004 | 2022 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 501.7M | 455.4M |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GLRE | ZURA |
|---|---|---|
| Price | $14.83 | $3.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 117.3K | ★ 1.8M |
| Earning Date | 11-02-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.00 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $729,777,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $81.89 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $3.15 |
| 52 Week High | $19.39 | $7.25 |
Technical Indicators
Market Signals| Indicator | GLRE | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 28.49 |
| Support Level | $14.62 | $3.25 |
| Resistance Level | $15.31 | $5.87 |
| Average True Range (ATR) | 0.31 | 0.28 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 60.75 | 4.21 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.